VANI|EPS -$0.43|Net Loss $6.6MVivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, subdermal drug implants using its proprietary NanoPortal™ technology.
For the year ended December 31, 2025, Vivani reported a net loss per common share (EPS) of $(0.43). The company reported no revenue for the period. The total net loss for the year was $26.6 million.
Research and development expenses increased to $18.1 million in 2025. Vivani ended the year with $16.2 million in cash and cash equivalents. Recent financings yielded $41.5 million in gross proceeds. This capital is expected to fund operations into mid-2027.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.